Treatment with triple combination of atorvastatin, perindopril, and amlodipine in patients with stable coronary artery disease: A subgroup analysis from the PAPA-CAD study.
Csaba András DézsiPublished in: The Journal of international medical research (2018)
Background In patients with stable coronary artery disease, aspirin, a statin, and an angiotensin-converting enzyme inhibitor are recommended as first-line agents for secondary prevention. Subgroup analyses of the previously published Hungarian Perindopril plus Amlodipine in PAtients with Coronary Artery Disease (PAPA-CAD) non-interventional trial demonstrated that the addition of the metabolically beneficial, fixed combination of perindopril + amlodipine to atorvastatin further improves the patient's lipid profile. Methods The PAPA-CAD study, a 6-month open-label, prospective, multicenter, observational/non-interventional survey evaluated data accumulated from patients with hypertensive patients with stable coronary artery disease. The herein-reported subgroup analysis was conducted using the findings from those 1130 patients, who were taking atorvastatin in addition to the fixed combination of perindopril + amlodipine at the time of all four study visits (i.e., at baseline and 1, 3, and 6 months later). Results In the subgroup of patients taking atorvastatin as an add-on agent, 82.5% reached the target blood pressure of 140/90 mmHg compared with 78.8% of those not taking a statin. The addition of atorvastatin to the fixed combination of perindopril + amlodipine resulted in further significant improvements of key metabolic parameters. Conclusion This subgroup analysis confirmed that favorable synergism exists among perindopril, amlodipine, and atorvastatin.
Keyphrases
- hypertensive patients
- coronary artery disease
- blood pressure
- cardiovascular events
- percutaneous coronary intervention
- phase iii
- coronary artery bypass grafting
- open label
- clinical trial
- heart rate
- angiotensin converting enzyme
- end stage renal disease
- cross sectional
- arterial hypertension
- cardiovascular disease
- chronic kidney disease
- low dose
- ejection fraction
- case report
- metabolic syndrome
- newly diagnosed
- skeletal muscle
- systematic review
- phase ii
- heart failure
- antiplatelet therapy
- weight loss
- acute coronary syndrome
- radiation therapy
- phase ii study
- blood glucose
- aortic stenosis
- big data
- peritoneal dialysis
- patient reported outcomes
- insulin resistance
- artificial intelligence
- replacement therapy
- transcatheter aortic valve replacement